reports
GUERBET : Nombre d'actions et de droits de vote composant le capital d...
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mars 2024 GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mars 2024 En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les sociétés dont des actions sont admises aux négociations sur un marché réglementé publient sur leur site Internet et transmettent à l'AMF, à la fin de chaque mois, le nombre total de droits de vote et le nombre d'actions composant le capital de la société s'ils ...
Guerbet: 1 director
A director at Guerbet sold 1,350 shares at 32.322EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Ipsen and Skyhawk Therapeutics announce RNA targeting research collabo...
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaborationFollowing development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disordersThis promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape1...
Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de co...
Ipsen et Skyhawk Therapeutics annoncent la signature d'un accord de collaboration de recherche visant le ciblage d’ARN dans les maladies neurologiques rares Ipsen conclut un accord d'option pour les droits mondiaux exclusifs des candidats retenus dans le cadre de cette collaborationUne fois le candidat au développement validé, Ipsen sera responsable de la poursuite de son développement et de sa commercialisation en s’appuyant sur son expertise dans les neurosciences et les troubles du mouvementLa plateforme technologique prometteuse créée par Skyhawk permet d'adresser, via de petites molécu...
Virbac: 1 director
A director at Virbac sold 3,008 shares at 365.039EUR and the significance rating of the trade was 96/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
- Dominic Rose
- Naresh Chouhan
Sartorius Stedim - More Downside to Come (SELL, TP EUR150 [165], 9 pgs...
The capitulation may be upon us. The order book continues to show weakness & contrary to the befuddling Q423 sales strength, equipment sales look likely to stay weak as CDMO’s reduce CAPEX after 3yrs of turbo charged growth. We now question the trend growth rate as we believe that market share gains will be minimal, CDMO CAPEX will recover very slowly & M&A is unlikely to contribute as much as it did in the past. Moreover, we expect DIM to add significant capacity in the coming 24mths, which is ...
Amplitude Surgical - Chiffre d’affaires consolidé 9 mois de l’exercice...
VALENCE, France--(BUSINESS WIRE)-- Regulatory News: Amplitude Surgical (ISIN : FR0012789667, Mnémo : AMPLI, éligible PEA-PME), leader français sur le marché des technologies chirurgicales destinées à l’orthopédie pour les membres inférieurs, annonce son chiffre d’affaires consolidé pour le troisième trimestre de l’exercice 2023-24. Olivier Jallabert, Directeur Général d’Amplitude Surgical, déclare : « Au cours des 9 premiers mois de l’exercice 2023-24, Amplitude Surgical a poursuivi sa trajectoire de croissance et affiche une progression de son chiffre d’affaires de +6,1% à taux constants ...
- Maissa Keskes
- Stephane Houri
EDEN EDENRED SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
BN DANONE SA
KPN ROYAL KPN NV
VOLV B VOLVO AB CLASS B
ABB ABB LTD.
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
CAP CAPGEMINI SE
EZJ EASYJET PLC
REP REPSOL SA
DIM SARTORIUS STEDIM BIOTECH SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
ASML ASML HOLDING NV
BP. BP P.L.C.
FDJ LA FRANCAISE DES JEUX SA
SHEL SHELL PLC
SGSN SGS SA
- Maissa Keskes
- Stephane Houri
EDEN EDENRED SA
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
BN DANONE SA
KPN ROYAL KPN NV
VOLV B VOLVO AB CLASS B
ABB ABB LTD.
SRT3 SARTORIUS AG PREF
NOKIA NOKIA OYJ
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
SCHP SCHINDLER HOLDING AG PREF
CAP CAPGEMINI SE
EZJ EASYJET PLC
REP REPSOL SA
DIM SARTORIUS STEDIM BIOTECH SA
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
BC BRUNELLO CUCINELLI S.P.A.
HLAG HAPAG-LLOYD AG
BHP BHP GROUP LTD
ASML ASML HOLDING NV
BP. BP P.L.C.
FDJ LA FRANCAISE DES JEUX SA
SHEL SHELL PLC
SGSN SGS SA
- Oliver Metzger
Sartorius Stedim Biotech : Q1 review -Some stabilisation, but sales an...
>Q1 with some stabilisation – sales and order intake weaker than expected - Q1 2024 revenues of € 667m (-8.1% y-o-y,-2%/-4% vs ODDO BHF/consensus) were impacted by an organic decline of 9.4%. The decline in constant currencies was at -6.7%. Sartorius Stedim Biotech was impacted by mixed dynamics across its portfolio and regions. Demand continued to normalise the consumables business with positive order momentum, which indicates further progress in destocking. Simultan...
Sartorius Stedim Biotech publishes unaudited first quarter results for...
Sartorius Stedim Biotech SA / Key word(s): Quarter Results Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 18-Apr-2024 / 07:02 CET/CEST Aubagne, France | April 18, 2024 Sartorius Stedim Biotech publishes unaudited first quarter results for 2024 Sales revenue of 667 million euros, in constant currencies1 - 9.4 percent organically1and - 6.7 percent including acquisitions2(reported: - 8.2 percent) Order intake up 13.9 percent to 676 million euros (reported: 12.5 percent) with significant growth in recurring business, while demand from China remains we...
Sartorius Stedim Biotech publie ses résultats non audités pour le prem...
Sartorius Stedim Biotech SA / Mot-clé(s) : Résultat trimestriel Sartorius Stedim Biotech publie ses résultats non audités pour le premier trimestre 2024 18-Avr-2024 / 07:02 CET/CEST Aubagne, France | 18 avril 2024 Sartorius Stedim Biotech publie ses résultats non audités pour le premier trimestre 2024 Chiffre d’affaires à 667 millions d’euros, soit une baisse organique de 9,4 % à taux de change constant1 et une baisse de 6,7 % à taux de change constant en tenant compte des acquisitions2(baisse déclarée : - 8,2 %) Augmentation des prises de commandes de 13,9 % à 676 millions d...
- Aurore Aventin (IDMidCaps)
Virbac - A promising start to the year
Nearly 10% organic sales growth in Q1, ahead of our forecastsAll regions up at constant exchange ratesVisibility improving for the rest of the year, and annual guidance logically confirmedWe remain at Add, with a slightly higher target price of €375/share (vs. €365 previously).
Bastide Le Confort Medical: 1 director
A director at Bastide Le Confort Medical bought 3,000 shares at 14.420EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Ipsen publishes its 2023 Universal Registration Document
Ipsen publishes its 2023 Universal Registration Document Ipsen publishes its 2023 Universal Registration Document PARIS, FRANCE, 17 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty biopharmaceutical group, announces that its 2023 Universal Registration Document has been filed with the French Autorité des Marchés Financiers on 17 April 2024 and registered under the number D.24-0288. The document is available on and . Copies will also be available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt, France. The following documents are incorpora...
Ipsen publie son Document d’enregistrement universel 2023
Ipsen publie son Document d’enregistrement universel 2023 Ipsen publie sonDocument d’enregistrement universel 2023 PARIS, FRANCE, 17 avril 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY) groupe biopharmaceutique mondial de spécialité annonce que son Document d’enregistrement universel 2023 a été déposé le 17 avril 2024 auprès de l’Autorité des Marchés Financiers (AMF) et enregistré sous le numéro D.24-0288. Ce document peut être consulté sur le site internet de la société à l’adresse et sur le site de l’AMF . Il sera également tenu à disposition au siège social de la Société – 65 quai Geo...
- Oliver Metzger
ODDO BHF Small & MIDCAP MORNING NEWS - 04/17/2024 Date Performance sin...
NEXT can claim the leading position in the UK fashion category. Moreover, the company managed the transition from offline to online comparatively well. However, top-line growth should remain at 4% a year until 2026 as the business outside the UK is too small. The operating margin should decrease 40bp to 17.6% on higher wages and general Opex inflation. We initiate coverage with a Neutral rating and a TP of 8,900p (based on a peer group and DCF). - ...
- Oliver Metzger
ODDO BHF Small & MIDCAP MORNING NEWS - 17/04/2024 Date Performance dep...
NEXT can claim the leading position in the UK fashion category. Moreover, the company managed the transition from offline to online comparatively well. However, top-line growth should remain at 4% a year until 2026 as the business outside the UK is too small. The operating margin should decrease 40bp to 17.6% on higher wages and general Opex inflation. We initiate coverage with a Neutral rating and a TP of 8,900p (based on a peer group and DCF). - ...
- Christophe-Raphaël Ganet
Emeis : 2023 results relatively in line – 2024 set to be last year of ...
>Operating indicators showing stabilising results - Emeis (formerly Orpéa) this morning posted its 2023 results, with EBITDAR of € 696m vs € 780m in 2022, or 13.4% of sales vs 16.7% in 2022, EBITDA pre-IFRS 16 of € 204m (vs € 342m), EBIT of -€ 919m and net income of € 1.355bn (vs € 1.25bn est.). Cash flow came in at -€ 746m. To recap, the latest guidance was for EBITDAR of around € 690m est. and EBIT of around € 210m.Shareholders’ equity after financial restr...
- Christophe-Raphaël Ganet
Emeis : Résultats 2023 relativement en ligne – L’exercice 2024 apparai...
>Des indicateurs opérationnels montrant une stabilisation des résultats - Emeis (ex-Orpéa) publie ce jour ses résultats 2023 : l’EBITDAR ressort à 696 M€ vs 780 M€ en 2022, soit 13,4% du CA vs 16,7% en 2022, l’EBITDA pre-IFRS 16 à 204 M€ (vs 342 M€), le ROP à -919 M€ et le RNpg à 1 355 M€ (vs 1,25 Md€e). Le cash-flow s’établit à -746 M€. Pour rappel, les dernières guidances indiquaient un EBITDAR aux environs de 690 M€e et EBIT autour de 210 M€.Les capitaux pro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.